Assessment of Clinical and Biomarker Response to Anti Tumour Necrosis Factor Alpha Biological in Spondyloarthritis using ASDAS CRP Criteria

Author : Vinod Raghav, Krishnan Shanmuganandan, Pratap Shankar, Rakesh Kumar Dixit

Advanced laboratory techniques are playing an important role in the diagnosis of the disease which is a first and important step towards the treatment of the diseases. These diseases can be anything. Spondyloarthritis (SpA) are a heterogeneous group of diseases characterized by the presence of inflammatory back pain, asymmetrical peripheral arthritis, enthesitis, dactylitis and uveitis. Infection with an unknown organism or exposure to an unknown antigen in a genetically susceptible patient (HLA-B27–positive) is hypothesized to result in the clinical expression of a spondyloarthritis. The association between HLA-B27 and ankylosing spondylitis remains the strongest known relationship between a major histocompatibility complex (MHC) antigen and a disease. The aim of the present study was to assess the response to Infliximab (anti TNF- alpha monoclonal antibody) in Patients with Spondyloarthritis using ASDAS-CRP criteria.

Full Text Attachment

Creative Commons License World Journal of Pharmaceutical Science is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at Permissions beyond the scope of this license may be available at